BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

915 related articles for article (PubMed ID: 6192963)

  • 1. Management of breast cancer.
    Cohen IA; Keller JH; Abate MA
    Clin Pharm; 1982; 1(6):515-29. PubMed ID: 6192963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer of the breast. Endocrine and hormonal therapy.
    Kardinal CG; Donegan WL
    Major Probl Clin Surg; 1979; 5():361-404. PubMed ID: 379452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiestrogen treatment of breast cancer: an overview.
    Pearson OH; Manni A; Arafah BM
    Cancer Res; 1982 Aug; 42(8 Suppl):3424s-3429s. PubMed ID: 7044524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Hormones and tumor therapy: current clinical status and future developments in endocrine therapy of breast cancer].
    Szepesi T; Schratter-Sehn AU
    Wien Klin Wochenschr; 1982 Sep; 94(17):463-9. PubMed ID: 6760557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Present status of endocrine therapy of breast cancer: a surgeon's view].
    Nomura Y
    Gan To Kagaku Ryoho; 1984 May; 11(5):981-8. PubMed ID: 6426405
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes: 20-year results of a Southwest Oncology Group study.
    Rivkin SE; Green SJ; Lew D; Costanzi JJ; Athens JW; Osborne CK; Vaughn CB; Martino S
    Cancer; 2003 Jan; 97(1):21-9. PubMed ID: 12491501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Hormone therapy of patients with breast cancer].
    Moiseenko VM; Semiglazov VF
    Vopr Onkol; 1984; 30(11):3-9. PubMed ID: 6393574
    [No Abstract]   [Full Text] [Related]  

  • 8. Endocrine therapy of breast and prostate cancer.
    Manni A
    Endocrinol Metab Clin North Am; 1989 Jun; 18(2):569-92. PubMed ID: 2663486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular Action and Clinical Relevance of Aromatase Inhibitors.
    Murphy MJ
    Oncologist; 1998; 3(2):129-130. PubMed ID: 10388095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.
    Viale G; Regan MM; Maiorano E; Mastropasqua MG; Golouh R; Perin T; Brown RW; Kovács A; Pillay K; Ohlschlegel C; Braye S; Grigolato P; Rusca T; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS
    J Clin Oncol; 2008 Mar; 26(9):1404-10. PubMed ID: 18349391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aromatase inhibitors for treatment of breast cancer: current concepts and new perspectives.
    Santen RJ
    Breast Cancer Res Treat; 1986; 7 Suppl():S23-35. PubMed ID: 3527304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Management of advanced breast cancer in post-menopausal women. A comparative trial of hormonal therapy, chemotherapy, and a combination of both].
    Clavel B; Cappelaere JP; Guerin J; Klein T; Pommatau E; Berlie J
    Sem Hop; 1982 Sep; 58(34):1919-23. PubMed ID: 6293073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endocrine management of breast cancer.
    Schneider PG; Jackisch C; Brandt B
    Int J Fertil Menopausal Stud; 1994; 39 Suppl 2():115-27. PubMed ID: 7874188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
    Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P
    Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Chemical adrenalectomy induced by aminoglutethimide in the treatment of breast cancer. A review].
    Cikes M
    Schweiz Med Wochenschr; 1983 Mar; 113(11):382-91. PubMed ID: 6342129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Content of epidermal growth factor receptor in metastatic breast cancer: its role in endocrine sensitivity prediction.
    Nesković-Konstantinović ZB; Nikolić-Vukosavljević DB; Branković-Magić MV; Mitrovic LB; Spuzić I
    Neoplasma; 2000; 47(2):107-13. PubMed ID: 10985476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of endocrine therapy.
    Pritchard KI; Sutherland DJ
    Hematol Oncol Clin North Am; 1989 Dec; 3(4):765-805. PubMed ID: 2481670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy.
    Gasparini G; Toi M; Miceli R; Vermeulen PB; Dittadi R; Biganzoli E; Morabito A; Fanelli M; Gatti C; Suzuki H; Tominaga T; Dirix LY; Gion M
    Cancer J Sci Am; 1999; 5(2):101-11. PubMed ID: 10198732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response of patients with carcinoma of the breast to hormonal therapy and combination chemotherapy.
    Henderson MD; Buroker TR; Samson MK; Mood DW; Baker LH; Vaitkevicius VK
    Surg Gynecol Obstet; 1975 Aug; 141(2):232-4. PubMed ID: 1154233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The state of hormone and chemotherapy in breast neoplasms].
    Brunner KW
    Schweiz Med Wochenschr; 1978 Sep; 108(35):1338-50. PubMed ID: 210499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 46.